These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32433232)

  • 1. Antithymocyte Globulin Versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients With Hepatitis C Virus.
    Bae S; Durand CM; Garonzik-Wang JM; Chow EKH; Kucirka LM; McAdams-DeMarco MA; Massie AB; Al Ammary F; Coresh J; Segev DL
    Transplantation; 2020 Jun; 104(6):1294-1303. PubMed ID: 32433232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
    Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Antithymocyte Globulin Dose on the Incidence of CMV Infection in High-risk Kidney Transplant Recipients Without Pharmacological Prophylaxis.
    de Paula MI; Bae S; Shaffer AA; Garonzik-Wang J; Felipe CR; Cristelli MP; Waldram MM; Massie AB; Medina-Pestana J; Segev DL; Tedesco-Silva H
    Transplantation; 2020 Oct; 104(10):2139-2147. PubMed ID: 31978003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of Benefit and Potential Harm of Induction Therapy in Simultaneous Liver-Kidney Transplants.
    AbdulRahim N; Anderson L; Kotla S; Liu H; Ariyamuthu VK; Ghanta M; MacConmara M; Tujios SR; Mufti A; Mohan S; Marrero JA; Vagefi PA; Tanriover B
    Liver Transpl; 2019 Mar; 25(3):411-424. PubMed ID: 30506870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients.
    Horton PJ; Tchervenkov J; Barkun JS; Rochon C; Chaudhury PK; Znajda TL; Martinie JB; Metrakos P
    J Gastrointest Surg; 2005; 9(7):896-902. PubMed ID: 16137581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C.
    Luan FL; Schaubel DE; Zhang H; Jia X; Pelletier SJ; Port FK; Magee JC; Sung RS
    Transplantation; 2008 Jun; 85(11):1601-6. PubMed ID: 18551066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience.
    Huang HF; Zhou JY; Xie WQ; Wu JY; Deng H; Chen JH
    Int Urol Nephrol; 2016 Aug; 48(8):1363-1370. PubMed ID: 27170340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
    Cannon RM; Locke JE; Orandi BJ; Anderson DJ; Davis EG; Mackelaite L; Dave H; Eng M; Jones CM
    Transplantation; 2020 Jun; 104(6):1215-1228. PubMed ID: 31517783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Optimal Donor-Recipient Combinations Among Human Immunodeficiency Virus (HIV)-Positive Kidney Transplant Recipients.
    Locke JE; Shelton BA; Reed RD; MacLennan PA; Mehta S; Sawinski D; Segev DL
    Am J Transplant; 2016 Aug; 16(8):2377-83. PubMed ID: 27140837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney transplantation in hepatitis C-positive recipients: does type of induction influence outcomes?
    Sureshkumar KK; Thai NL; Marcus RJ
    Transplant Proc; 2012 Jun; 44(5):1262-4. PubMed ID: 22663997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of induction therapy and antiretroviral regimen on outcomes in kidney transplant recipients living with human immunodeficiency.
    Marks CR; Durand CM; Bowring MG; Hand J; Abidi MZ; Malinis M; Barnaba B; Patel H; Pavlakis M; Alonso CD
    Transpl Infect Dis; 2024 Aug; 26(4):e14287. PubMed ID: 38698669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 2 receptor antagonists for kidney transplant recipients.
    Webster AC; Ruster LP; McGee R; Matheson SL; Higgins GY; Willis NS; Chapman JR; Craig JC
    Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003897. PubMed ID: 20091551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed Graft Function in Simultaneous Liver Kidney Transplantation.
    Weeks SR; Luo X; Haugen CE; Ottmann SE; Gurakar AO; Naqvi FF; Alqahtani SA; Philosophe B; Cameron AM; Desai NM; Segev DL; Garonzik Wang JM
    Transplantation; 2020 Mar; 104(3):542-550. PubMed ID: 31403551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
    Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
    Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction Therapy in Elderly Kidney Transplant Recipients With Low Immunological Risk.
    Masset C; Boucquemont J; Garandeau C; Buron F; Morelon E; Girerd S; Ladrière M; Mourad G; Garrigue V; Cassuto E; Albano L; Foucher Y; Dantal J;
    Transplantation; 2020 Mar; 104(3):613-622. PubMed ID: 31283665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
    Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
    Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus.
    Kucirka LM; Durand CM; Bae S; Avery RK; Locke JE; Orandi BJ; McAdams-DeMarco M; Grams ME; Segev DL
    Am J Transplant; 2016 Aug; 16(8):2368-76. PubMed ID: 27111897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression Regimen Use and Outcomes in Older and Younger Adult Kidney Transplant Recipients: A National Registry Analysis.
    Lentine KL; Cheungpasitporn W; Xiao H; McAdams-DeMarco M; Lam NN; Segev DL; Bae S; Ahn JB; Hess GP; Caliskan Y; Randall HB; Kasiske BL; Schnitzler MA; Axelrod DA
    Transplantation; 2021 Aug; 105(8):1840-1849. PubMed ID: 33214534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients.
    Marfo K; Akalin E; Wang C; Lu A
    Am J Health Syst Pharm; 2011 Dec; 68(23):2276-82. PubMed ID: 22095818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.